1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) von Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., Albiges, L.

Volltext

OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update von Spigel, D.R., Ahn, M.-J., Majem, M., Medina Rodríguez, L., Lee, K.H., Carcereny, E., Hernández, A.A., Insa, A., Cho, E.K., Besse, B., Rha, S.Y., Weiss, J., D'Arcangelo, M., Im, S.-A., Kim, S.-W., Carneiro, B.A., Gadgeel, S.M., Mitchell, P., Asare, J.M., Gainer, S.D., Achour, I., Subramaniam, D.S., Felip, E.

Volltext